We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+49.94%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
(+33%)
Cap. Flow
-$3.86M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.2M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$14.5M |
| 3 |
Cytokinetics
CYTK
|
+$13.8M |
| 4 |
Dyne Therapeutics
DYN
|
+$13.8M |
| 5 |
Zai Lab
ZLAB
|
+$11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HilleVax
HLVX
|
+$21.1M |
| 2 |
CG Oncology
CGON
|
+$20M |
| 3 |
Disc Medicine
IRON
|
+$12.9M |
| 4 |
Cogent Biosciences
COGT
|
+$12.5M |
| 5 |
Travere Therapeutics
TVTX
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Miscellaneous | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$5.19B
| $498M | 14.93% |
6,795,121
| – | – |
2022 Q1
14 quarters
|
|
2
NewAmsterdam Pharma
NAMS
$2.39B
| $475M | 14.23% |
16,701,956
+94,882
| +0.6% | +$2.27M |
2022 Q4
11 quarters
|
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $361M | 10.82% |
3,383,950
| – | – |
2022 Q3
12 quarters
|
|
4
BridgeBio Pharma
BBIO
$12.7B
| $200M | 5.98% |
3,845,457
+45,000
| +1% | +$2.19M |
2023 Q1
10 quarters
|
|
5
Arcutis Biotherapeutics
ARQT
$3.32B
| $186M | 5.58% |
9,874,511
| – | – |
2022 Q1
14 quarters
|
|
6
Phathom Pharmaceuticals
PHAT
$599M
| $147M | 4.4% |
12,466,489
| – | – |
2022 Q1
14 quarters
|
|
7
Krystal Biotech
KRYS
$9.79B
| $122M | 3.64% |
688,460
| – | – |
2022 Q1
14 quarters
|
|
8
Maze Therapeutics
MAZE
$1.46B
| $118M | 3.55% |
4,567,274
-1
| -0% | -$17 |
2025 Q1
2 quarters
|
|
9
MBX Biosciences
MBX
$2.35B
| $116M | 3.49% |
6,652,013
+666,666
| +11% | +$8.91M |
2024 Q3
4 quarters
|
|
|
10
Disc Medicine
IRON
$2.14B
| $95.1M | 2.85% |
1,438,534
-216,300
| -13% | -$12.9M |
2023 Q2
9 quarters
|
|
11
Trevi Therapeutics
TRVI
$1.72B
| $93.9M | 2.81% |
10,259,409
| – | – |
2022 Q2
13 quarters
|
|
12
Tarsus Pharmaceuticals
TARS
$3.38B
| $69.4M | 2.08% |
1,167,527
-230,000
| -16% | -$11.3M |
2022 Q1
14 quarters
|
|
13
DELISTED
KalVista Pharmaceuticals
KALV
| $61.4M | 1.84% |
5,039,867
+152,000
| +3% | +$2.1M |
2022 Q1
14 quarters
|
|
|
14
Zai Lab
ZLAB
$2.53B
| $55.1M | 1.65% |
1,627,320
+319,182
| +24% | +$11M |
2025 Q1
2 quarters
|
|
15
Agios Pharmaceuticals
AGIO
$1.85B
| $51.4M | 1.54% |
1,279,754
| – | – |
2023 Q3
8 quarters
|
|
16
Erasca
ERAS
$5.14B
| $49.6M | 1.48% |
22,729,436
| – | – |
2024 Q2
5 quarters
|
|
|
17
Cytokinetics
CYTK
$8.82B
| $48.9M | 1.47% |
890,445
+335,714
| +61% | +$13.8M |
2025 Q2
1 quarter
|
|
18
Revolution Medicines
RVMD
$41.5B
| $46.6M | 1.4% |
997,455
| – | – |
2023 Q1
10 quarters
|
|
19
Palvella Therapeutics
PVLA
$1.77B
| $45.3M | 1.36% |
722,400
| – | – |
2024 Q3
4 quarters
|
|
20
Savara
SVRA
$978M
| $40.9M | 1.23% |
11,462,301
| – | – |
2023 Q3
8 quarters
|
|
|
21
Dyne Therapeutics
DYN
$2.81B
| $34.4M | 1.03% |
2,718,105
+1,212,121
| +80% | +$13.8M |
2025 Q1
2 quarters
|
|
|
22
Abivax
ABVX
$7.68B
| $32.1M | 0.96% |
+378,300
| New | +$23.2M |
2025 Q3
0 quarters
|
|
23
Aura Biosciences
AURA
$640M
| $31.5M | 0.94% |
5,100,000
| – | – |
2025 Q2
1 quarter
|
|
24
Ultragenyx Pharmaceutical
RARE
$1.47B
| $29.6M | 0.89% |
983,715
| – | – |
2024 Q2
5 quarters
|
|
25
Lexeo Therapeutics
LXEO
$216M
| $29.4M | 0.88% |
4,424,725
| – | – |
2024 Q3
4 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2025 Portfolio in Review
As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
- Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
- Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
- Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
- Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
- Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
- Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.